S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Compare Stocks

Enter up to ten stock symbols separated by a comma or space (ex. STE,ZBH,SNN,WILYY,CLPBY).

Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
STE
STERIS
$227.68
+0.4%
$232.62
$170.36
$248.29
$22.77B0.64483,796 shs511,746 shs
WILYY
Demant A/S
$22.57
-2.6%
$24.43
$17.51
$30.02
$10.84B0.11418 shs646 shs
CLPBY
Coloplast A/S
$14.78
-2.4%
$16.62
$13.64
$18.90
$31.93B0.2888,695 shs116,799 shs
ZBH
Zimmer Biomet
$122.54
-0.4%
$126.29
$116.60
$180.36
$25.60B1.251.71 million shs2.97 million shs
SNN
Smith & Nephew
$33.92
-0.9%
$33.98
$31.55
$45.67
$14.92B0.73671,047 shs499,851 shs

MarketRank™

CompanyOverall ScoreAnalyst's OpinionCommunity RankDividend StrengthCompany OwnershipEarnings & Valuation
STE
STERIS
2.52 of 5 Stars
1.54.03.32.51.3
WILYY
Demant A/S
0.72 of 5 Stars
0.03.60.00.00.0
CLPBY
Coloplast A/S
1.55 of 5 Stars
0.04.02.50.01.3
ZBH
Zimmer Biomet
2.90 of 5 Stars
4.34.81.72.51.3
SNN
Smith & Nephew
1.30 of 5 Stars
0.03.61.70.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
STE
STERIS
3.00
Buy$248.809.28% Upside
WILYY
Demant A/S
2.25
HoldN/AN/A
CLPBY
Coloplast A/S
2.22
Hold$1,055.677,041.33% Upside
ZBH
Zimmer Biomet
2.52
Buy$166.2235.65% Upside
SNN
Smith & Nephew
2.67
BuyN/AN/A

Current Analyst Ratings

Latest STE, ZBH, SNN, WILYY, and CLPBY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
1/21/2022
ZBH
Zimmer Biomet
Needham & Company LLC
Lower Price TargetBuy$158.00 ➝ $155.00
1/19/2022
CLPBY
Coloplast A/S
JPMorgan Chase & Co.
Lower Price Target1,038.00 ➝ 1,033.00
1/19/2022
ZBH
Zimmer Biomet
Wells Fargo & Company
DowngradeEqual Weight ➝ Underweight$170.00 ➝ $124.00
1/10/2022
CLPBY
Coloplast A/S
Barclays
Boost Price Target975.00 ➝ 990.00
1/10/2022
ZBH
Zimmer Biomet
Mizuho
DowngradeBuy ➝ Neutral
1/10/2022
ZBH
Zimmer Biomet
BTIG Research
DowngradeBuy ➝ Neutral
1/7/2022
ZBH
Zimmer Biomet
Morgan Stanley
DowngradeOverweight ➝ Equal Weight$165.00 ➝ $145.00
1/4/2022
WILYY
Demant A/S
JPMorgan Chase & Co.
UpgradeUnderweight ➝ Neutral
1/4/2022
ZBH
Zimmer Biomet
Piper Sandler
DowngradeOverweight ➝ Neutral$185.00 ➝ $135.00
12/21/2021
ZBH
Zimmer Biomet
Truist Financial
Lower Price TargetBuy$175.00 ➝ $145.00
12/9/2021
ZBH
Zimmer Biomet
Royal Bank of Canada
Initiated CoverageSector Perform$140.00
(Data available from 1/23/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
STE
STERIS
$3.11B7.33$8.52 per share26.71$45.59 per share4.99
WILYY
Demant A/S
$2.22B4.89$0.34 per share66.15$2.63 per share8.58
CLPBY
Coloplast A/S
$2.76B11.56$0.28 per share52.47$0.48 per share30.80
ZBH
Zimmer Biomet
$7.02B3.64$13.28 per share9.23$58.85 per share2.08
SNN
Smith & Nephew
$4.56B3.27$2.50 per share13.58$12.04 per share2.82

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
STE
STERIS
$397.40M$2.8081.3125.90N/A6.50%12.44%7.02%2/1/2022 (Estimated)
WILYY
Demant A/S
$171.74MN/A0.00N/AN/AN/AN/AN/A
CLPBY
Coloplast A/S
$585.21M$0.3052.7941.06N/A21.62%69.30%33.77%N/A
ZBH
Zimmer Biomet
-$138.90M$3.8931.5015.172.3410.39%12.67%6.54%2/7/2022 (Confirmed)
SNN
Smith & Nephew
$448MN/A0.0018.241.55N/AN/AN/A2/17/2022 (Estimated)

Latest STE, ZBH, SNN, WILYY, and CLPBY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/7/2022N/A
ZBH
Zimmer Biomet
$1.96N/A-$1.96N/AN/AN/A  
11/4/20219/30/2021
ZBH
Zimmer Biomet
$1.76$1.81+$0.05$2.93$1.94 billion$1.92 billion    
11/2/20219/30/2021
STE
STERIS
$1.82$1.99+$0.17$3.29$1.16 billion$1.20 billion    
(Earnings results data provided by Zacks Investment Research)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
STE
STERIS
$1.720.76%+27.69%61.43%17 Years
WILYY
Demant A/S
N/AN/AN/AN/AN/A
CLPBY
Coloplast A/S
$0.221.49%N/A73.33%N/A
ZBH
Zimmer Biomet
$0.960.78%N/A24.68%1 Years
SNN
Smith & Nephew
$0.561.65%+2.18%N/AN/A

Latest STE, ZBH, SNN, WILYY, and CLPBY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/16/2021
ZBH
Zimmer Biomet
quarterly$0.240.73%12/27/202112/28/20211/31/2022
10/28/2021
STE
STERIS
Quarterly$0.430.74%11/22/202111/23/202112/17/2021
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
STE
STERIS
0.52
2.42
1.71
WILYY
Demant A/S
0.43
0.79
0.57
CLPBY
Coloplast A/S
0.02
1.29
0.90
ZBH
Zimmer Biomet
0.51
1.81
0.95
SNN
Smith & Nephew
0.55
2.10
1.27

Ownership

Institutional Ownership

CompanyInstitutional Ownership
STE
STERIS
89.23%
WILYY
Demant A/S
N/A
CLPBY
Coloplast A/S
0.1%
ZBH
Zimmer Biomet
88.09%
SNN
Smith & Nephew
8.55%

Insider Ownership

CompanyInsider Ownership
STE
STERIS
1.14%
WILYY
Demant A/S
N/A
CLPBY
Coloplast A/S
N/A
ZBH
Zimmer Biomet
0.56%
SNN
Smith & Nephew
1%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
STE
STERIS
13,000100.02 million98.88 millionOptionable
WILYY
Demant A/S
16,591480.26 millionN/ANot Optionable
CLPBY
Coloplast A/S
12,5002.16 billionN/ANot Optionable
ZBH
Zimmer Biomet
20,000208.91 million207.74 millionOptionable
SNN
Smith & Nephew
18,000439.87 million435.47 millionOptionable

STE, ZBH, SNN, WILYY, and CLPBY Headlines

SourceHeadline
Smith+Nephew acquires cementless partial knee maker Engage SurgicalSmith+Nephew acquires cementless partial knee maker Engage Surgical
massdevice.com - January 19 at 5:33 PM
Smith & Nephew ‘corruption’ inquiry asked for documentsSmith & Nephew ‘corruption’ inquiry asked for documents
thetimes.co.uk - January 9 at 8:10 PM
Lester Murray Antman dba SimplyRich Buys Rogers Communications Inc, Equity Residential, ...Lester Murray Antman dba SimplyRich Buys Rogers Communications Inc, Equity Residential, ...
finance.yahoo.com - January 7 at 5:54 PM
Smith+Nephew outlines growth strategy, sets mid-term guidanceSmith+Nephew outlines growth strategy, sets mid-term guidance
massdevice.com - December 17 at 1:39 PM
Berenberg slightly raises target price on Smith & NephewBerenberg slightly raises target price on Smith & Nephew
sharecast.com - December 17 at 8:39 AM
Smith+Nephew Targets Consistent 4-6% Organic Revenue Growth By 2024 - Quick FactsSmith+Nephew Targets Consistent 4-6% Organic Revenue Growth By 2024 - Quick Facts
nasdaq.com - December 16 at 9:47 AM
Heres Whats Concerning About Smith & Nephews (LON:SN.) Returns On CapitalHere's What's Concerning About Smith & Nephew's (LON:SN.) Returns On Capital
finance.yahoo.com - December 15 at 9:19 AM
December 2022 Options Now Available For Smith & Nephew (SNN)December 2022 Options Now Available For Smith & Nephew (SNN)
nasdaq.com - December 13 at 2:30 PM
Smith & Nephew plc - ADR Shares Fall 1.6% Below Previous 52-Week Low - Market MoverSmith & Nephew plc - ADR Shares Fall 1.6% Below Previous 52-Week Low - Market Mover
nasdaq.com - November 27 at 4:12 AM
Smith+Nephew (SNN) Introduces Real Intelligence & CORI SystemSmith+Nephew (SNN) Introduces Real Intelligence & CORI System
finance.yahoo.com - November 25 at 10:08 AM
Smith+Nephew launches Real Intelligence and CORI(TM) Surgical System; next generation handheld robotics platform in CanadaSmith+Nephew launches Real Intelligence and CORI(TM) Surgical System; next generation handheld robotics platform in Canada
stockhouse.com - November 24 at 1:15 PM
Smith+Nephew launches Real Intelligence and CORI™ Surgical System; next generation handheld robotics platform in CanadaSmith+Nephew launches Real Intelligence and CORI™ Surgical System; next generation handheld robotics platform in Canada
finance.yahoo.com - November 24 at 8:15 AM
Smith+Nephew launches Cori handheld robotic system for knee arthroplastiesSmith+Nephew launches Cori handheld robotic system for knee arthroplasties
massdevice.com - November 23 at 10:12 AM
Smith+Nephew creates digital surgery and robotics innovation center in GermanySmith+Nephew creates digital surgery and robotics innovation center in Germany
massdevice.com - November 16 at 2:50 PM
Smith & Nephew plc: Smith+Nephew establishes its first Medical Education Centre for the Asia Pacific region in SingaporeSmith & Nephew plc: Smith+Nephew establishes its first Medical Education Centre for the Asia Pacific region in Singapore
finanznachrichten.de - November 11 at 6:09 AM
Smith & Nephew PLC (SNN) Q3 2021 Earnings Call TranscriptSmith & Nephew PLC (SNN) Q3 2021 Earnings Call Transcript
finance.yahoo.com - November 4 at 3:48 PM
Smith+Nephew introduces the LEGION™ CONCELOC™ Cementless Total Knee System with proprietary 3D printed Advanced Porous Titanium technologySmith+Nephew introduces the LEGION™ CONCELOC™ Cementless Total Knee System with proprietary 3D printed Advanced Porous Titanium technology
finance.yahoo.com - November 2 at 8:06 AM
3 Stocks That Could Bounce Back in the Fourth Quarter3 Stocks That Could Bounce Back in the Fourth Quarter
stocknews.com - October 6 at 8:09 PM
Smith+Nephew to expand Real Intelligence digital ecosystem and CORI™ Surgical System with total hip arthroplastySmith+Nephew to expand Real Intelligence digital ecosystem and CORI™ Surgical System with total hip arthroplasty
finance.yahoo.com - September 1 at 8:35 AM
New data underscores material benefits of Smith+Nephews OXINIUM™ DH Technology and OR3O™ Dual Mobility System for total hip arthroplasty versus Cobalt Chrome linersNew data underscores material benefits of Smith+Nephew's OXINIUM™ DH Technology and OR3O™ Dual Mobility System for total hip arthroplasty versus Cobalt Chrome liners
finance.yahoo.com - August 31 at 7:13 AM
Smith+Nephew touts analysis of Oxinium in total hip arthroplastySmith+Nephew touts analysis of Oxinium in total hip arthroplasty
massdevice.com - August 30 at 4:06 PM
Smith+Nephews OXINIUM™ Technology recognized as the best performing bearing with lowest risk of revision in total hip arthroplastySmith+Nephew's OXINIUM™ Technology recognized as the best performing bearing with lowest risk of revision in total hip arthroplasty
finance.yahoo.com - August 30 at 7:08 AM
Smith & Nephew: wounded but recoveringSmith & Nephew: wounded but recovering
afr.com - August 26 at 2:46 AM
Smith & Nephew Owes Nothing In Hip Resurfacing Device TrialSmith & Nephew Owes Nothing In Hip Resurfacing Device Trial
law360.com - August 18 at 6:57 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.